948 related articles for article (PubMed ID: 24430917)
1. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS
JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917
[TBL] [Abstract][Full Text] [Related]
2. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N;
BMC Psychiatry; 2018 May; 18(1):140. PubMed ID: 29776349
[TBL] [Abstract][Full Text] [Related]
3. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.
Trigo JM; Soliman A; Quilty LC; Fischer B; Rehm J; Selby P; Barnes AJ; Huestis MA; George TP; Streiner DL; Staios G; Le Foll B
PLoS One; 2018; 13(1):e0190768. PubMed ID: 29385147
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.
Allsop DJ; Lintzeris N; Copeland J; Dunlop A; McGregor IS
Clin Pharmacol Ther; 2015 Jun; 97(6):571-4. PubMed ID: 25777582
[TBL] [Abstract][Full Text] [Related]
5. Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial.
Lintzeris N; Bhardwaj A; Mills L; Dunlop A; Copeland J; McGregor I; Bruno R; Gugusheff J; Phung N; Montebello M; Chan T; Kirby A; Hall M; Jefferies M; Luksza J; Shanahan M; Kevin R; Allsop D;
JAMA Intern Med; 2019 Sep; 179(9):1242-1253. PubMed ID: 31305874
[TBL] [Abstract][Full Text] [Related]
6. Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial.
Lintzeris N; Mills L; Dunlop A; Copeland J; Mcgregor I; Bruno R; Kirby A; Montebello M; Hall M; Jefferies M; Kevin R; Bhardwaj A;
Drug Alcohol Depend; 2020 Oct; 215():108220. PubMed ID: 32768992
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.
Schoedel KA; Chen N; Hilliard A; White L; Stott C; Russo E; Wright S; Guy G; Romach MK; Sellers EM
Hum Psychopharmacol; 2011 Apr; 26(3):224-36. PubMed ID: 21671456
[TBL] [Abstract][Full Text] [Related]
8. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
Levin FR; Mariani JJ; Pavlicova M; Brooks D; Glass A; Mahony A; Nunes EV; Bisaga A; Dakwar E; Carpenter KM; Sullivan MA; Choi JC
Drug Alcohol Depend; 2016 Feb; 159():53-60. PubMed ID: 26711160
[TBL] [Abstract][Full Text] [Related]
9. [Nabiximols as a substitute for cannabis].
Dumont GJH
Ned Tijdschr Geneeskd; 2020 Sep; 164():. PubMed ID: 33201625
[TBL] [Abstract][Full Text] [Related]
10. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.
Levin FR; Mariani JJ; Brooks DJ; Pavlicova M; Cheng W; Nunes EV
Drug Alcohol Depend; 2011 Jul; 116(1-3):142-50. PubMed ID: 21310551
[TBL] [Abstract][Full Text] [Related]
11. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.
Trigo JM; Lagzdins D; Rehm J; Selby P; Gamaleddin I; Fischer B; Barnes AJ; Huestis MA; Le Foll B
Drug Alcohol Depend; 2016 Apr; 161():298-306. PubMed ID: 26925704
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.
Werneck MA; Kortas GT; de Andrade AG; Castaldelli-Maia JM
CNS Drugs; 2018 Dec; 32(12):1113-1129. PubMed ID: 30361897
[TBL] [Abstract][Full Text] [Related]
13. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
Flachenecker P; Henze T; Zettl UK
Eur Neurol; 2014; 72(1-2):95-102. PubMed ID: 24943098
[TBL] [Abstract][Full Text] [Related]
14. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain.
Lichtman AH; Lux EA; McQuade R; Rossetti S; Sanchez R; Sun W; Wright S; Kornyeyeva E; Fallon MT
J Pain Symptom Manage; 2018 Feb; 55(2):179-188.e1. PubMed ID: 28923526
[TBL] [Abstract][Full Text] [Related]
15. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.
Schlienz NJ; Lee DC; Stitzer ML; Vandrey R
Drug Alcohol Depend; 2018 Jun; 187():254-260. PubMed ID: 29689485
[TBL] [Abstract][Full Text] [Related]
16. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study.
Winstock AR; Lea T; Copeland J
J Psychopharmacol; 2009 Jan; 23(1):84-93. PubMed ID: 18515451
[TBL] [Abstract][Full Text] [Related]
17. Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial.
Montebello M; Jefferies M; Mills L; Bruno R; Copeland J; McGregor I; Rivas C; Jackson MA; Silsbury C; Dunlop A; Lintzeris N;
Drug Alcohol Depend; 2022 May; 234():109388. PubMed ID: 35316689
[TBL] [Abstract][Full Text] [Related]
18. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.
Portenoy RK; Ganae-Motan ED; Allende S; Yanagihara R; Shaiova L; Weinstein S; McQuade R; Wright S; Fallon MT
J Pain; 2012 May; 13(5):438-49. PubMed ID: 22483680
[TBL] [Abstract][Full Text] [Related]
19. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder.
Mills L; Dunlop A; Montebello M; Copeland J; Bruno R; Jefferies M; Mcgregor I; Lintzeris N
Subst Abuse Treat Prev Policy; 2022 Oct; 17(1):67. PubMed ID: 36209081
[TBL] [Abstract][Full Text] [Related]
20. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
Flachenecker P; Henze T; Zettl UK
Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
